{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T22:26:21Z","timestamp":1783117581630,"version":"3.54.6"},"reference-count":29,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2008,1,16]],"date-time":"2008-01-16T00:00:00Z","timestamp":1200441600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2008,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Autoimmune bullous skin disorders are induced by autoantibodies against distinct adhesion complexes of the epidermal and dermal\u2010epidermal junction. Since most of these disorders are characterized by a severe, potentially lethal course,they require long\u2010term immunosuppressive treatment to reduce the de novo synthesis of pathogenic autoantibodies by B lymphocytes. Rituximab, a chimeric monoclonal antibody against CD20 on B lymphocytes, has shown promise in several case reports or cohort studies in the treatment of paraneo\u2010plastic pemphigus,refractory cases of pemphigus vulgaris and foliaceus and in other autoimmune bullous disorders.Treatment with rituximab leads to depletion of pathogenic B\u2010cells which may last up to 12 months resulting in a reduction of plasma cells secreting pathogenic autoantibodies.Rituximab is usually administered in an adjuvant setting at a dose of 375 mg\/m<jats:sup>2<\/jats:sup> i.v.in weekly intervals for four consecutive weeks in addition to the standard immunosuppressive treatment.The present consensus statement of German\u2010speaking derma\u2010tologists,rheumatologists and oncologists summarizes and evaluates the current evidence for the use and mode of application of rituximab in autoimmune bullous skin disorders.<\/jats:p>","DOI":"10.1111\/j.1610-0387.2007.06602.x","type":"journal-article","created":{"date-parts":[[2008,4,25]],"date-time":"2008-04-25T09:36:35Z","timestamp":1209116195000},"page":"366-373","source":"Crossref","is-referenced-by-count":122,"title":["Recommendations for the use of rituximab (anti\u2010CD20 antibody) in the treatment of autoimmune bullous skin diseases<sup>\u00a7<\/sup>"],"prefix":"10.1111","volume":"6","author":[{"given":"Michael","family":"Hertl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Detlef","family":"Zillikens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Borradori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leena","family":"Bruckner\u2010Tuderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Burckhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcdiger","family":"Eming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Engert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Goebeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Hunzelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Karlhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ocko","family":"Kautz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Undine","family":"Lippert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Niedermeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Nitschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Pf\u00fctze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Reiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enno","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iakov","family":"Shimanovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sticherling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Wolff\u2010Franke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,1,16]]},"reference":[{"key":"e_1_2_10_2_2","first-page":"224","article-title":"Anti\u2010B\u2010cell\u2010directed immunotherapy (rituximab) in the treatment of refractory pemphigus \u2013 an update","volume":"15","author":"Arin MJ","year":"2005","journal-title":"Eur J Dermatol"},{"key":"e_1_2_10_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"e_1_2_10_4_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008416911099"},{"key":"e_1_2_10_5_2","doi-asserted-by":"crossref","first-page":"7537A","DOI":"10.1200\/jco.2006.24.18_suppl.7537","article-title":"Serum levels and pharmacokinetic of ritu\u2010ximab in Bi\u2010weekly R\u2010CHOP in elderly patients with DLBCL treated in the RI\u2010COVER\u201060 trial","volume":"24","author":"Reiser M","year":"2006","journal-title":"J Clin Oncol"},{"key":"e_1_2_10_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032534"},{"key":"e_1_2_10_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21617"},{"key":"e_1_2_10_8_2","doi-asserted-by":"publisher","DOI":"10.1159\/000100876"},{"key":"e_1_2_10_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20430"},{"key":"e_1_2_10_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri1838"},{"key":"e_1_2_10_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062930"},{"key":"e_1_2_10_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067752"},{"key":"e_1_2_10_13_2","first-page":"269","article-title":"Anti\u2010CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma\u2010associated paraneoplastic pemphigus","volume":"137","author":"Borradori L","year":"2001","journal-title":"Arch Dermatol"},{"key":"e_1_2_10_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06651.x"},{"key":"e_1_2_10_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2006.02151.x"},{"key":"e_1_2_10_16_2","volume-title":"Bio\u2010logics in General Medicine","author":"Eming R","year":"2007"},{"key":"e_1_2_10_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00105-007-1284-2"},{"key":"e_1_2_10_18_2","doi-asserted-by":"publisher","DOI":"10.1159\/000099591"},{"key":"e_1_2_10_19_2","first-page":"266","article-title":"Delayed response of oral pemphigus vulgaris to rituximab treatment","volume":"16","author":"Niedermeier A","year":"2006","journal-title":"Eur J Dermatol"},{"key":"e_1_2_10_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2003.05580.x"},{"key":"e_1_2_10_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06740.x"},{"key":"e_1_2_10_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11181"},{"key":"e_1_2_10_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.2.147"},{"key":"e_1_2_10_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.2.192"},{"key":"e_1_2_10_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07646.x"},{"key":"e_1_2_10_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08358.x"},{"key":"e_1_2_10_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2003.05209_10.x"},{"key":"e_1_2_10_28_2","unstructured":"Pf\u00fctzeM EmingR NiedermeierA UKuhlmann HoyerJ HertlM.Both immunoadsorption and rituximab induce prolonged clinical responses in pemphigus vulgaris. (einger. z. Publ.)."},{"key":"e_1_2_10_29_2","first-page":"3","article-title":"Rituxan warning","volume":"41","year":"2007","journal-title":"FDA Consum"},{"key":"e_1_2_10_30_2","first-page":"4","article-title":"Introducing a novel autoimmune bullous skin disorder intensity score (ABSIS) in pemphigus","volume":"17","author":"Pf\u00fctze M","year":"2007","journal-title":"Eur J Dermatol."}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1610-0387.2007.06602.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1610-0387.2007.06602.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T11:18:56Z","timestamp":1695727136000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1610-0387.2007.06602.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,16]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["10.1111\/j.1610-0387.2007.06602.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1610-0387.2007.06602.x","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,16]]}}}